{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:20:51Z","timestamp":1773314451801,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100018208","name":"Cure JM Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018208","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015391","name":"Myositis Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015391","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammation"],"DOI":"10.1007\/s10753-026-02469-8","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:03:54Z","timestamp":1771470234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interferon-Driven Tryptophan Metabolism Links Inflammation and Mental Health in Juvenile Dermatomyositis"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0650-7713","authenticated-orcid":false,"given":"Yang","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aviya L.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Payton","family":"Hermanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhinav","family":"Janappareddi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5231-2469","authenticated-orcid":false,"given":"Jorge A.","family":"Gonzalez-Chapa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-594X","authenticated-orcid":false,"given":"Susan","family":"Shenoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4252-2889","authenticated-orcid":false,"given":"Mengtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3883-2318","authenticated-orcid":false,"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6171-1952","authenticated-orcid":false,"given":"Christian","family":"Lood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"issue":"8","key":"2469_CR1","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/rheumatology\/34.8.732","volume":"34","author":"DP Symmons","year":"1995","unstructured":"Symmons, D.P., J.A. Sills, and S.M. Davis. 1995. The incidence of juvenile dermatomyositis: Results from a nation-wide study. British Journal of Rheumatology 34 (8): 732\u2013736. https:\/\/doi.org\/10.1093\/rheumatology\/34.8.732.","journal-title":"British Journal of Rheumatology"},{"issue":"9341","key":"2469_CR2","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/S0140-6736(02)11279-7","volume":"360","author":"JM Gardner-Medwin","year":"2002","unstructured":"Gardner-Medwin, J.M., P. Dolezalova, C. Cummins, et al. 2002. Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 360 (9341): 1197\u20131202. https:\/\/doi.org\/10.1016\/S0140-6736(02)11279-7.","journal-title":"Lancet"},{"issue":"6","key":"2469_CR3","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/art.24555","volume":"60","author":"TB Niewold","year":"2009","unstructured":"Niewold, T. B., S. N. Kariuki, G. A. Morgan, et al. 2009. Elevated serum interferon\u2010\u03b1 activity in juvenile dermatomyositis: Associations with disease activity at diagnosis and after thirty\u2010six months of therapy. Arthritis and Rheumatism 60 (6): 1815\u20131824. https:\/\/doi.org\/10.1002\/art.24555. (Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum.).","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"2469_CR4","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/art.40800","volume":"71","author":"GM Moneta","year":"2019","unstructured":"Moneta, G.M., D. Pires Marafon, E. Marasco, et al. 2019. Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features. Arthritis & Rheumatology 71 (6): 1011\u20131021. https:\/\/doi.org\/10.1002\/art.40800.","journal-title":"Arthritis & Rheumatology"},{"issue":"2","key":"2469_CR5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12016-020-08798-2","volume":"59","author":"J Jiang","year":"2020","unstructured":"Jiang, J., M. Zhao, C. Chang, et al. 2020. Type i interferons in the pathogenesis and treatment of autoimmune diseases. Clinical Reviews in Allergy & Immunology 59 (2): 248\u2013272. https:\/\/doi.org\/10.1007\/s12016-020-08798-2.","journal-title":"Clinical Reviews in Allergy & Immunology"},{"issue":"1","key":"2469_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12969-024-01008-9","volume":"22","author":"S Zhang","year":"2024","unstructured":"Zhang, S., X. Li, H. Chen, et al. 2024. Assay for interferon gamma release as a novel marker in pediatric patients with systemic lupus erythematosus. Pediatric Rheumatology Online Journal 22 (1): 70. https:\/\/doi.org\/10.1186\/s12969-024-01008-9.","journal-title":"Pediatric Rheumatology Online Journal"},{"key":"2469_CR7","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.121544","author":"AA Throm","year":"2018","unstructured":"Throm, A.A., H. Moncrieffe, A.B. Orandi, et al. 2018. Identification of enhanced IFN-\u03b3 signaling in polyarticular juvenile idiopathic arthritis with mass cytometry. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.121544.","journal-title":"JCI Insight"},{"issue":"5","key":"2469_CR8","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/art.40060","volume":"69","author":"LG Rider","year":"2017","unstructured":"Rider, L.G., R. Aggarwal, A. Pistorio, et al. 2017. 2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: An International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation collaborative initiative. Arthritis & Rheumatology 69 (5): 911\u2013923. https:\/\/doi.org\/10.1002\/art.40060.","journal-title":"Arthritis & Rheumatology"},{"issue":"5","key":"2469_CR9","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40272-017-0240-6","volume":"19","author":"C Papadopoulou","year":"2017","unstructured":"Papadopoulou, C., and L. R. Wedderburn. 2017. Treatment of juvenile dermatomyositis: An update. Paediatric Drugs 19 (5): 423\u2013434. https:\/\/doi.org\/10.1007\/s40272-017-0240-6.","journal-title":"Paediatric Drugs"},{"issue":"1","key":"2469_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-017-0214-9","volume":"15","author":"AM Davis","year":"2017","unstructured":"Davis, A.M., T.B. Rubinstein, M. Rodriguez, et al. 2017. Mental health care for youth with rheumatologic diseases - Bridging the gap. Pediatric Rheumatology Online Journal 15 (1): 85. https:\/\/doi.org\/10.1186\/s12969-017-0214-9.","journal-title":"Pediatric Rheumatology Online Journal"},{"issue":"1","key":"2469_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-021-00503-7","volume":"19","author":"OA Fawole","year":"2021","unstructured":"Fawole, O.A., M.V. Reed, J.G. Harris, et al. 2021. Engaging patients and parents to improve mental health intervention for youth with rheumatological disease. Pediatric Rheumatology Online Journal 19 (1): 19. https:\/\/doi.org\/10.1186\/s12969-021-00503-7.","journal-title":"Pediatric Rheumatology Online Journal"},{"key":"2469_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-12-42","volume":"12","author":"A Knight","year":"2014","unstructured":"Knight, A., P. Weiss, K. Morales, et al. 2014. Depression and anxiety and their association with healthcare utilization in pediatric lupus and mixed connective tissue disease patients: A cross-sectional study. Pediatric Rheumatology Online Journal 12: 42. https:\/\/doi.org\/10.1186\/1546-0096-12-42.","journal-title":"Pediatric Rheumatology Online Journal"},{"issue":"7","key":"2469_CR13","doi-asserted-by":"publisher","first-page":"732","DOI":"10.2174\/1570159x14666151208113700","volume":"14","author":"O Kohler","year":"2016","unstructured":"Kohler, O., J. Krogh, O. Mors, et al. 2016. Inflammation in depression and the potential for anti-inflammatory treatment. Current Neuropharmacology 14 (7): 732\u2013742. https:\/\/doi.org\/10.2174\/1570159x14666151208113700.","journal-title":"Current Neuropharmacology"},{"issue":"8","key":"2469_CR14","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1001\/jamapsychiatry.2013.1111","volume":"70","author":"ME Benros","year":"2013","unstructured":"Benros, M.E., B.L. Waltoft, M. Nordentoft, et al. 2013. Autoimmune diseases and severe infections as risk factors for mood disorders: A nationwide study. JAMA Psychiatry 70 (8): 812\u2013820. https:\/\/doi.org\/10.1001\/jamapsychiatry.2013.1111.","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"2469_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125109","volume":"10","author":"C Lood","year":"2015","unstructured":"Lood, C., H. Tyden, B. Gullstrand, et al. 2015. Type i interferon-mediated skewing of the serotonin synthesis is associated with severe disease in systemic lupus erythematosus. PLoS ONE 10 (4): e0125109. https:\/\/doi.org\/10.1371\/journal.pone.0125109.","journal-title":"PLoS ONE"},{"key":"2469_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-025-01090-3","author":"BA Yates","year":"2025","unstructured":"Yates, B.A. 2025. Tryptophan metabolism, exercise and depression. Nature Reviews Endocrinology. https:\/\/doi.org\/10.1038\/s41574-025-01090-3.","journal-title":"Nature Reviews Endocrinology"},{"issue":"1","key":"2469_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/nutrit\/nuac042","volume":"81","author":"DJ Haleem","year":"2022","unstructured":"Haleem, D.J. 2022. Nutritional importance of tryptophan for improving treatment in depression and diabetes. Nutrition Reviews 81 (1): 133\u2013149. https:\/\/doi.org\/10.1093\/nutrit\/nuac042.","journal-title":"Nutrition Reviews"},{"issue":"9","key":"2469_CR18","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/nn1964","volume":"10","author":"T Canli","year":"2007","unstructured":"Canli, T., and K. P. Lesch. 2007. Long story short: The serotonin transporter in emotion regulation and social cognition. Nature Neuroscience 10 (9): 1103\u20131109. https:\/\/doi.org\/10.1038\/nn1964.","journal-title":"Nature Neuroscience"},{"issue":"2","key":"2469_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0098-2997(83)90005-5","volume":"6","author":"DA Bender","year":"1983","unstructured":"Bender, D.A. 1983. Biochemistry of tryptophan in health and disease. Molecular Aspects of Medicine 6 (2): 101\u2013197. https:\/\/doi.org\/10.1016\/0098-2997(83)90005-5.","journal-title":"Molecular Aspects of Medicine"},{"issue":"2","key":"2469_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/s0301-0082(00)00032-0","volume":"64","author":"TW Stone","year":"2001","unstructured":"Stone, T.W. 2001. Kynurenines in the CNS: From endogenous obscurity to therapeutic importance. Progress in Neurobiology 64 (2): 185\u2013218. https:\/\/doi.org\/10.1016\/s0301-0082(00)00032-0.","journal-title":"Progress in Neurobiology"},{"key":"2469_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.neuropharm.2013.03.030","volume":"74","author":"Q Zhou","year":"2013","unstructured":"Zhou, Q., and M. Sheng. 2013. NMDA receptors in nervous system diseases. Neuropharmacology 74:69\u201375. https:\/\/doi.org\/10.1016\/j.neuropharm.2013.03.030.","journal-title":"Neuropharmacology"},{"issue":"8","key":"2469_CR22","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1038\/s41380-020-00951-9","volume":"26","author":"W Marx","year":"2021","unstructured":"Marx, W., A. J. McGuinness, T. Rocks, et al. 2021. The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: A meta-analysis of 101 studies. Molecular Psychiatry 26 (8): 4158\u20134178. https:\/\/doi.org\/10.1038\/s41380-020-00951-9.","journal-title":"Molecular Psychiatry"},{"issue":"7","key":"2469_CR23","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1038\/s41380-020-00913-1","volume":"26","author":"F Bartoli","year":"2021","unstructured":"Bartoli, F., B. Misiak, T. Callovini, et al. 2021. The kynurenine pathway in bipolar disorder: A meta-analysis on the peripheral blood levels of tryptophan and related metabolites. Molecular Psychiatry 26 (7): 3419\u20133429. https:\/\/doi.org\/10.1038\/s41380-020-00913-1.","journal-title":"Molecular Psychiatry"},{"issue":"12","key":"2469_CR24","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.2337\/dc23-1147","volume":"46","author":"JJ Liu","year":"2023","unstructured":"Liu, J.J., J. Ching, H.N. Wee, et al. 2023. Plasma tryptophan-kynurenine pathway metabolites and risk for progression to end-stage kidney disease in patients with type 2 diabetes. Diabetes Care 46 (12): 2223\u20132231. https:\/\/doi.org\/10.2337\/dc23-1147.","journal-title":"Diabetes Care"},{"key":"2469_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00249","volume":"11","author":"L Lanser","year":"2020","unstructured":"Lanser, L., P. Kink, E.M. Egger, et al. 2020. Inflammation-induced tryptophan breakdown is related with anemia, fatigue, and depression in cancer. Frontiers in Immunology 11: 249. https:\/\/doi.org\/10.3389\/fimmu.2020.00249.","journal-title":"Frontiers in Immunology"},{"key":"2469_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf9794","author":"I Cervenka","year":"2017","unstructured":"Cervenka, I., L. Z. Agudelo, and J. L. Ruas. 2017. Kynurenines: Tryptophan\u2019s metabolites in exercise, inflammation, and mental health. Science. https:\/\/doi.org\/10.1126\/science.aaf9794.","journal-title":"Science"},{"key":"2469_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ph12010009","author":"GAH Korte-Bouws","year":"2019","unstructured":"Korte-Bouws, G.A.H., E. Albers, M. Voskamp, et al. 2019. Juvenile arthritis patients suffering from chronic inflammation have increased activity of both IDO and GTP-CH1 pathways but decreased BH4 efficacy: Implications for well-being, including fatigue, cognitive impairment, anxiety, and depression. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph12010009.","journal-title":"Pharmaceuticals (Basel)"},{"key":"2469_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211468","author":"IE Lundberg","year":"2017","unstructured":"Lundberg, I.E., A. Tj\u00e4rnlund, M. Bottai, et al. 2017. 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Annals of the Rheumatic Diseases. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211468.","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"2469_CR29","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty, R. E., T. R. Southwood, P. Manners, et al. 2004. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. Journal of Rheumatology 31 (2): 390\u2013392.","journal-title":"Journal of Rheumatology"},{"key":"2469_CR30","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/978-1-4615-4709-9_71","volume":"467","author":"B Widner","year":"1999","unstructured":"Widner, B., N. Sepp, E. Kowald, et al. 1999. Degradation of tryptophan in patients with systemic lupus erythematosus. Advances in Experimental Medicine and Biology 467:571\u2013577. https:\/\/doi.org\/10.1007\/978-1-4615-4709-9_71.","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"2469_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000808","author":"EW Anderson","year":"2022","unstructured":"Anderson, E.W., Y. Jin, A. Shih, et al. 2022. Associations between circulating interferon and kynurenine\/tryptophan pathway metabolites: Support for a novel potential mechanism for cognitive dysfunction in SLE. Lupus Science & Medicine. https:\/\/doi.org\/10.1136\/lupus-2022-000808.","journal-title":"Lupus Science & Medicine"},{"issue":"1","key":"2469_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-024-01461-1","volume":"40","author":"W Li","year":"2024","unstructured":"Li, W., L. Yang, H. Chen, et al. 2024. Depression, stress, and tryptophan metabolism through the kynurenine pathway: Treatment strategies from the perspective of Chinese herbal medicine. Metabolic Brain Disease 40 (1): 5. https:\/\/doi.org\/10.1007\/s11011-024-01461-1.","journal-title":"Metabolic Brain Disease"},{"key":"2469_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1357293","volume":"15","author":"Y Li","year":"2024","unstructured":"Li, Y., L. Wang, J. Huang, et al. 2024. Serum neuroactive metabolites of the tryptophan pathway in patients with acute phase of affective disorders. Frontiers in Psychiatry 15: 1357293. https:\/\/doi.org\/10.3389\/fpsyt.2024.1357293.","journal-title":"Frontiers in Psychiatry"},{"key":"2469_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158493","author":"AS Correia","year":"2022","unstructured":"Correia, A.S., and N. Vale. 2022. Tryptophan metabolism in depression: A narrative review with a focus on serotonin and kynurenine pathways. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms23158493.","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"2469_CR35","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1096\/fj.201700853R","volume":"32","author":"X Zang","year":"2018","unstructured":"Zang, X., X. Zheng, Y. Hou, et al. 2018. Regulation of proinflammatory monocyte activation by the kynurenine-AhR axis underlies immunometabolic control of depressive behavior in mice. The FASEB Journal 32 (4): 1944\u20131956. https:\/\/doi.org\/10.1096\/fj.201700853R.","journal-title":"The FASEB Journal"},{"issue":"3","key":"2469_CR36","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.it.2012.10.001","volume":"34","author":"DH Munn","year":"2013","unstructured":"Munn, D.H., and A.L. Mellor. 2013. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends in Immunology 34 (3): 137\u2013143. https:\/\/doi.org\/10.1016\/j.it.2012.10.001.","journal-title":"Trends in Immunology"},{"issue":"3","key":"2469_CR37","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1042\/bj2300635","volume":"230","author":"F Yamazaki","year":"1985","unstructured":"Yamazaki, F., T. Kuroiwa, O. Takikawa, et al. 1985. Human indolylamine 2,3-dioxygenase. Its tissue distribution, and characterization of the placental enzyme. Biochemical Journal 230 (3): 635\u2013638. https:\/\/doi.org\/10.1042\/bj2300635.","journal-title":"Biochemical Journal"},{"key":"2469_CR38","doi-asserted-by":"crossref","unstructured":"Yoshida, R., and O. Hayaishi. 1987. Indoleamine 2, 3-dioxygenase. In Methods in Enzymology, vol. 142, 188\u2013195. Elsevier.","DOI":"10.1016\/S0076-6879(87)42028-4"},{"issue":"4","key":"2469_CR39","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/s0891-5849(99)00272-5","volume":"28","author":"Y Dang","year":"2000","unstructured":"Dang, Y., W. E. Dale, and O. R. Brown. 2000. Comparative effects of oxygen on indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase of the kynurenine pathway. Free Radical Biology and Medicine 28 (4): 615\u2013624. https:\/\/doi.org\/10.1016\/s0891-5849(99)00272-5.","journal-title":"Free Radical Biology and Medicine"},{"issue":"3","key":"2469_CR40","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1471-4159.1978.tb07815.x","volume":"30","author":"EM Gal","year":"1978","unstructured":"Gal, E.M., and A.D. Sherman. 1978. Synthesis and metabolism of L-kynurenine in rat-brain. Journal of Neurochemistry 30 (3): 607\u2013613. https:\/\/doi.org\/10.1111\/j.1471-4159.1978.tb07815.x.","journal-title":"Journal of Neurochemistry"},{"issue":"1","key":"2469_CR41","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nrd3793","volume":"12","author":"L V\u00e9csei","year":"2013","unstructured":"V\u00e9csei, L., L. Szal\u00e1rdy, F. F\u00fcl\u00f6p, et al. 2013. Kynurenines in the CNS: Recent advances and new questions. Nature Reviews Drug Discovery 12 (1): 64\u201382. https:\/\/doi.org\/10.1038\/nrd3793.","journal-title":"Nature Reviews Drug Discovery"},{"key":"2469_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910625","author":"F Shimizu","year":"2024","unstructured":"Shimizu, F., and M. Nakamori. 2024. Blood-brain barrier disruption in neuroimmunological disease. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms251910625.","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"2469_CR43","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/mp.2009.116","volume":"15","author":"CL Raison","year":"2010","unstructured":"Raison, C.L., R. Dantzer, K.W. Kelley, et al. 2010. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-\u03b1: Relationship to CNS immune responses and depression. Molecular Psychiatry 15 (4): 393\u2013403. https:\/\/doi.org\/10.1038\/mp.2009.116.","journal-title":"Molecular Psychiatry"},{"issue":"6","key":"2469_CR44","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.2353\/ajpath.2007.070281","volume":"171","author":"M Scheler","year":"2007","unstructured":"Scheler, M., J. Wenzel, T. T\u00fcting, et al. 2007. Indoleamine 2,3-dioxygenase (IDO): The antagonist of type I interferon-driven skin inflammation? American Journal of Pathology 171 (6): 1936\u20131943. https:\/\/doi.org\/10.2353\/ajpath.2007.070281.","journal-title":"American Journal of Pathology"},{"issue":"5","key":"2469_CR45","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood.V83.5.1408.1408","volume":"83","author":"T Musso","year":"1994","unstructured":"Musso, T., G.L. Gusella, A. Brooks, et al. 1994. Interleukin-4 inhibits indoleamine 2,3-dioxygenase expression in human monocytes. Blood 83 (5): 1408\u20131411.","journal-title":"Blood"},{"issue":"5","key":"2469_CR46","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nri1604","volume":"5","author":"LC Platanias","year":"2005","unstructured":"Platanias, L.C. 2005. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nature Reviews Immunology 5 (5): 375\u2013386. https:\/\/doi.org\/10.1038\/nri1604.","journal-title":"Nature Reviews Immunology"},{"key":"2469_CR47","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.nmd.2024.06.006","volume":"41","author":"M Iguchi","year":"2024","unstructured":"Iguchi, M., J. Honjo, T. Yamamoto, et al. 2024. Baricitinib as a treatment for myasthenia gravis: A case report. Neuromuscular Disorders 41: 56\u201358. https:\/\/doi.org\/10.1016\/j.nmd.2024.06.006.","journal-title":"Neuromuscular Disorders"},{"issue":"2","key":"2469_CR48","doi-asserted-by":"publisher","first-page":"348","DOI":"10.55563\/clinexprheumatol\/hxin6o","volume":"41","author":"JJ Paik","year":"2023","unstructured":"Paik, J. J., G. Lubin, A. Gromatzky, et al. 2023. Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review. Clin Exp Rheumatol. 41 (2): 348\u2013358. https:\/\/doi.org\/10.55563\/clinexprheumatol\/hxin6o.","journal-title":"Clin Exp Rheumatol."},{"key":"2469_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003302","author":"E Morand","year":"2023","unstructured":"Morand, E., J.S. Smolen, M. Petri, et al. 2023. Safety profile of baricitinib in patients with systemic lupus erythematosus: An integrated analysis. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2023-003302.","journal-title":"RMD Open"},{"issue":"12","key":"2469_CR50","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15960","volume":"35","author":"M Agud-Dios","year":"2022","unstructured":"Agud-Dios, M., J. Arroyo-Andres, C. Rubio-Mu\u00f1iz, et al. 2022. Juvenile dermatomyositis-associated calcinosis successfully treated with combined immunosuppressive, bisphosphonate, oral baricitinib and physical therapy. Dermatologic Therapy 35 (12): e15960. https:\/\/doi.org\/10.1111\/dth.15960.","journal-title":"Dermatologic Therapy"},{"issue":"2","key":"2469_CR51","first-page":"402","volume":"41","author":"MV Mastrolia","year":"2023","unstructured":"Mastrolia, M. V., S. I. Orsini, E. Marrani, et al. 2023. Efficacy of Janus kinase inhibitor baricitinib in the treatment of refractory juvenile dermatomyositis complicated by calcinosis. Clin Exp Rheumatol. 41 (2): 402\u2013403.","journal-title":"Clin Exp Rheumatol."},{"issue":"2","key":"2469_CR52","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.immuni.2012.01.011","volume":"36","author":"DJ Gough","year":"2012","unstructured":"Gough, D. J., N. L. Messina, C. J. Clarke, et al. 2012. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 36 (2): 166\u2013174. https:\/\/doi.org\/10.1016\/j.immuni.2012.01.011.","journal-title":"Immunity"},{"issue":"1","key":"2469_CR53","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/art.41062","volume":"72","author":"M Bach","year":"2020","unstructured":"Bach, M., J. Moon, R. Moore, et al. 2020. A neutrophil activation biomarker panel in prognosis and monitoring of patients with rheumatoid arthritis. Arthritis & Rheumatology 72 (1): 47\u201356. https:\/\/doi.org\/10.1002\/art.41062.","journal-title":"Arthritis & Rheumatology"},{"issue":"14","key":"2469_CR54","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1111\/febs.13316","volume":"282","author":"HJ Yuasa","year":"2015","unstructured":"Yuasa, H.J., K. Mizuno, and H.J. Ball. 2015. Low efficiency IDO2 enzymes are conserved in lower vertebrates, whereas higher efficiency IDO1 enzymes are dispensable. FEBS Journal 282 (14): 2735\u20132745. https:\/\/doi.org\/10.1111\/febs.13316.","journal-title":"FEBS Journal"},{"key":"2469_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01861","volume":"11","author":"LMF Merlo","year":"2020","unstructured":"Merlo, L.M.F., J.B. DuHadaway, J.D. Montgomery, et al. 2020. Differential roles of IDO1 and IDO2 in T and B cell inflammatory immune responses. Frontiers in Immunology 11: 1861. https:\/\/doi.org\/10.3389\/fimmu.2020.01861.","journal-title":"Frontiers in Immunology"},{"issue":"7","key":"2469_CR56","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.biopsych.2024.11.020","volume":"98","author":"N Nikkheslat","year":"2025","unstructured":"Nikkheslat, N., Z. Zajkowska, C. Legido-Quigley, et al. 2025. Sex-specific alterations of the kynurenine pathway in association with risk for and remission of depression in adolescence. Biological Psychiatry 98 (7): 549\u2013557. https:\/\/doi.org\/10.1016\/j.biopsych.2024.11.020.","journal-title":"Biological Psychiatry"}],"container-title":["Inflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10753-026-02469-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-026-02469-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-026-02469-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:01:45Z","timestamp":1773248505000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10753-026-02469-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2469"],"URL":"https:\/\/doi.org\/10.1007\/s10753-026-02469-8","relation":{},"ISSN":["1573-2576"],"issn-type":[{"value":"1573-2576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In accordance with the Declaration of Helsinki, this study is IRB-approved (PIROSTUDY14426) at Seattle Children\u2019s Hospital and accessed through the Juvenile Myositis Seattle Children\u2019s Hospital Biorepository, headed by Dr. Lood and Shenoi, under IRB approval STUDY00003100 (November 9, 2017) and STUDY00003804 (December 21, 2022). Informed consent or assent was obtained from all patients\/caregivers as needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Dr. Lood received research funding from Boehringer Ingelheim, Pfizer, Gilead Sciences, Eli Lilly, Redd Pharma, Archon, Neutrolis, and Amytryx. Dr. Lood is a scientific advisor for Citryll and Redd Pharma. Dr. Shenoi has served as a consultant for Cabaletta Bio. The other authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Number"}}],"article-number":"100"}}